News
Public · Published
Omega Healthcare's Q3 earnings boosted by funds available for distribution, reduced leverage
Omega Healthcare reported Q3 adjusted FFO of $0.82 per diluted share versus $0.79 a year earlier, and funds available for distribution of $0.78 per share. Total revenue rose to $340.55M from $311.59M, while rental income fell. The company raised 2026 adjusted FFO guidance to $3.28 to $3.30.
Published:
Updated:
What happened
Omega Healthcare reported Q3 adjusted FFO of $0.82 per diluted share versus $0.79 a year earlier, and funds available for distribution of $0.78 per share. Total revenue rose to $340.55M from $311.59M, while rental income fell. The company raised 2026 adjusted FFO guidance to $3.28 to $3.30.
Confirmed
Global impact / market context
Higher funds available for distribution, which means cash generated for shareholders, and record-low borrowed money give Omega more room to fund accretive investments, meaning deals that add to per-share cash flow. Raised guidance signals management expects that cash growth to continue, supporting the dividend and share price.
Analyst inference
Falling rental income, the rent Omega collects from operators, missed analyst estimates even as total revenue grew on resident fees and services. That mix shift means future cash growth depends more on new investments and property performance than on existing rents, making the raised guidance and deal pipeline the key tests for investors.
Analyst inference
What to watch
- Omega's 2026 adjusted FFO guidance range is now $3.28 to $3.30 per share, up from $3.22 to $3.26. Watch whether actual results land within this raised range. Confirmed
- Management expects further accretive investments, meaning deals that increase per-share cash flow, through the rest of this year and into early 2027. Watch announced transaction volumes and their expected contribution. Proposed
- Rental income fell year over year and missed the analyst consensus. Watch whether rent collection and operator health stabilize, since rental income remains the largest revenue line. Analyst inference